| Biomarker ID | 1504 |
| PMID | 25139197 |
| Year | 2014 |
| Biomarker | Prostate Health Index (PHI) |
| Biomarker Basis | Concentration Based (pg/mL) |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Upregulated in patients with Grade pT3 or GS ≥ 7 |
| Odds Ratio/Hazard Ratio/Relative Risk | Univariate: HR= 0.03 (0.02–0.04), p-value< 0.001, AUC: 0.69 (0.64–0.74) |
| Effect on Pathways | NA |
| Experiment | Single adverse pathologic characteristic (pT3 disease or pathologic Gleason score I7) |
| Type of Biomarker | Prognostic |
| Cohort | The study cohort consisted of 489 patients with biopsy-proven clinically localised PCa who underwent either open or robot-assisted laparoscopic RP. 134 had stage pT3 and 336 had Gleason Score ≥ 7 |
| Senstivity | NA |
| Specificity | NA |
| AUC | 0.69 (95% CI: 0.64–0.74) |
| Accuracy | NA |
| Level Of Significance | p < 0.001 |
| Method Used | UniCel DxI800 Immunoassay System analyser |
| Clinical | No |
| Remarks | PHI = [(p2PSA / fPSA) / √tPSA] |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |